Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann,

Slides:



Advertisements
Similar presentations
By Gracie Canales August 10, 2010
Advertisements

Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.
` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.
GeneXpert for Detection of MTB and Rifampin Resistance
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
THE YIELD OF GENEXPERT IN PULMONARY TUBERCULOSIS&RIFAMPICIN RESISTANCE
1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.
Implementation of Diagnostics in Resource-Limited Settings Amy Piatek Global Health Bureau, Office of Health, Infectious Diseases & Nutrition U.S. Agency.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
Standards for Laboratory Diagnosis of Tuberculosis Professor Brian I. Duerden Inspector of Microbiology and Infection Control, Department of Health.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.
Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health.
Module 11: Clinical guide to Xpert MTB/RIF Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Jason R. Andrews, MD Stephen D. Lawn, MD, DTM&H Corina Rusu, BA, BS Robin Wood, FCP, MMed, DTM&H Farzad Noubary, PhD Melissa A. Bender, MD, MPH Robert.
Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.
KEY CHANGES IN THE NEW NTBLCP GUIDELINES
Melinda E. Clark, Ph.D. Division of Consolidated Laboratory Services
Early and Improved TB case detection through the use of GeneXpert technology in Nepal.
COMPREHENSIVE APPROACH TO TB DIAGNOSIS
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
LABORATORIES and DIAGNOSIS of TUBERCULOSIS Assoc. Prof. Alpaslan Alp Hacettepe University Faculty of Medicine Department of Medical Microbiology.
British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.
Tuberculosis Research of INA-RESPOND on Drug-resistant
CLINICAL DIAGNOSTIC TB LABORATORY Alexander Sloutsky, Director University of Massachusetts Supranational Reference TB Laboratory Boston, MA.
PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.
Revision of new diagnostics for TB
High cost of Xpert MTB/RIF ® testing per tuberculosis case diagnosed at Partners in Hope Medical Center, a public private HIV care clinic in Lilongwe,
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
TB Methodologies Dr. John G. Magee Regional Reference Centre for Mycobacteriology Health Protection Agency Regional Laboratory, Newcastle upon Tyne.
Molecular diagnosis of drug resistant tuberculosis by a DNA array
Challenge of Diagnosing Smear-Negative TB Department of Infectious Diseases.
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.
Distribution of MTB among newly diagnosed HIV patients at Malindi District Hospital during July 2012 to June Sheldon kalu 1 1 Malindi District Hospital.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS Identification of Mycobacterium tuberculosis complex in clinical specimens of HIV-infected patients at Instituto.
TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.
François-Xavier BLANC, MD, PhD Nantes University France
New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.
CASES OF PLEURAL EFFUSION (n=56)
Field Testing of OMNI-gene TB Sputum Optimizer in Malawi
Biosafety Implications of GeneXpert MTB/RIF assay: Experience of the National Tuberculosis Reference Laboratory , Lagos Nwokoye N, Onubogu CC, Nwadike.
Nucleic Acid Amplification Test for Tuberculosis
Volume 377, Issue 9776, Pages (April 2011)
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm  S.O. Simons, T. van der Laan,
Molecular Diagnosis in Resource-Limited Settings Camilla Rodrigues, M
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study  Prof Susan.
Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive.
Evaluation of a Urine-Based Rapid Molecular Diagnostic Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis  Krutarth Patel, Matilde.
Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country 
Division of Infectious Diseases
Timeline of development of key elements of the Cambodian MDR-TB treatment programme. *GLC1 application for patients enrolled in the CAMbodian Early vs.
Goal Objectives Expected Outcomes
Deciphering TB Lab Reports
Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective.
TB Screening and Differentiated Service Delivery: State of the Art
Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.
The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection  O. Opota, J. Mazza-Stalder,
Decade of field experience with TB GeneXpert IAS 2019 Satellite session Mexico, 22 July 2019 By Jean de Dieu IRAGENA Technical Officer Laboratory WHO/AFRO,
Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.
Presentation transcript:

Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann, Ph.D., Mark P. Nicol, Ph.D., Shubhada Shenai, Ph.D., Fiorella Krapp, M.D., Jenny Allen, B.Tech., Rasim Tahirli, M.D., Robert Blakemore, B.S., Roxana Rustomjee, M.D., Ph.D., Ana Milovic, M.S., Martin Jones, Ph.D., Sean M. O’Brien, Ph.D., David H. Persing, M.D., Ph.D., Sabine Ruesch-Gerdes, M.D., Eduardo Gotuzzo, M.D., Camilla Rodrigues, M.D., David Alland, M.D., and Mark D. Perkins, M.D September 1, 2010, at NEJM.org.. R3 Jo Uk / Prof. Park Myung-Jae

Introduction MDR Tbc (multidrug- resistant tuberculosis) : 500,000 patients Tbc coinfected with HIV : 1.37 million patients (worldwide each year) –Only a small fraction have access to sufficiently sensitive case detection or drug-susceptibility testing. –High frequency of AFB smear (-) in HIV-associated tuberculosis  Diagnostic delay is common. Failure of quick diagnosis and treatment –increased mortality –secondary resistance (including extensively drug-resistant tuberculosis) –ongoing transmission Mycobacterial culture and current nucleic acid–amplification technologies for the detection of tuberculosis and MDR Tbc –Complex / need the associated infrastructure –restrict the use of such tests to reference laboratories.  urgent need for simple and rapid diagnostic tools

Xpert MTB/RIF –fully automated molecular test for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF) –heminested real-time PCR assay  amplify an MTB specific sequence of the rpoB gene, which is probed with molecular beacons for mutations within the rifampin-resistance determining region –Process of Xpert MTB/RIF addition of a bactericidal buffer to sputum  The only manual stepaddition of a bactericidal buffer to sputum  The only manual step Transfer defined volume to the MTB/RIF cartridgeTransfer defined volume to the MTB/RIF cartridge cartridge is then inserted into the GeneXpert devicecartridge is then inserted into the GeneXpert device  provides results within 2 hours.

Process of Xpert MTB/RIF test The only manual step

Purpose determine its sensitivity and specificity in the intended target population as compared with the best available reference standard. (by Multicenter, prospective evaluation)

Methods Study Population –July 2008 ~ March 2009 in Peru / Azerbaijan / South Africa / India –consecutive adults with symptoms of pul, Tbc or MDR Tbc.  provide 3 sputum samples each ( >1.5 ml ) 2 specimen – processed with N-acetyl-l-cysteine /sodium hydroxide before microscopy, solid and liquid culture, MTB/RIF test2 specimen – processed with N-acetyl-l-cysteine /sodium hydroxide before microscopy, solid and liquid culture, MTB/RIF test 1 specimen – direct testing with microscopy and MTB/RIF test.1 specimen – direct testing with microscopy and MTB/RIF test.

Methods Categories for Analysis AFB (+) Culture (+) AFB (-) Culture (+) AFB (-) Culture (-) AFB (-) Culture (-) No Tbc Clinical Tbc MTB/RIF test

RESULTS

Final diagnostic categories

Sensitivity and specificity

Detection of MDR Tbc

Conclusion The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time